aTyr Pharma, Inc. (LIFE) Shares Surge on Resolaris™ Fast Track Designation
aTyr Pharma (NASDAQ: LIFE) shares are 7% higher mid-day after the biotherapeutics company this morning said its product candidate Resolaris™ was granted Fast Track designation by the FDA for the treatment of facioscapulohumeral muscular dystrophy (FSHD), making it the first known therapeutic candidate for the treatment of FSHD to receive the designation. Resolaris, a designated Orphan Drug in FSHD, is currently being studied in a phase 1b/2 clinical program for three types of rare myopathies with an immune component. To view the full press release, visit: http://nnw.fm/o4dDg About aTyr Pharma aTyr Pharma is engaged in the discovery and clinical development…